

## **TO THE NATIONAL SECURITIES MARKET COMMISSION**

For the purposes set out in Article 227 of Law 6/2023 of 17 March on Securities Markets and Investment Services, and related provisions, Faes Farma, S.A. hereby notifies the market of the following

### **OTHER RELEVANT INFORMATION**

#### **A) RESOLUTIONS OF THE GENERAL MEETING**

At the Company's Annual General Meeting, validly held at second call, all the proposals of the Board of Directors set out under the various items on the agenda were approved:

- Approval of the annual accounts, the individual and consolidated management reports, as well as the non-financial information statement and sustainability information for the financial year 2025.
- Re-election of three independent directors and the Chairman of the Board of Directors, and appointment of two proprietary directors. The composition of the Board of Directors is as follows:
  - Chairman: Mr Mariano Ucar Angulo
  - Executive Director: Mr Eduardo Recoder de la Cuadra
  - Members:
    - Mr Iñigo Zavala Ortiz de la Torre
    - Ms Belén Amatriaín Corbi
    - Ms María Eugenia Zugaza Salazar
    - Ms Nuria Pascual Lapeña
    - Mr Enrique Linares Plaza
    - Ms Beatriz Faro Morales
    - Mr Jacobo Llanza Figueroa
    - Mr Ángel Agudo Valenciano
  - Non-executive secretary: Mr Francisco Pérez-Crespo Payá.

For their part, the Board Committees and the lead director remain unchanged.

- Consultative vote on the annual report on directors' remuneration for the 2025 financial year.

- Approval of the amendment to the long-term incentive scheme involving the grant of Company shares to certain senior executives and key staff.
- Approval of the Directors' Remuneration Policy.
- Appointment of the auditor of the Company and its consolidated group.
- Delegation of powers to the Board of Directors for the implementation of the resolutions adopted.

## **B) KEY HIGHLIGHTS**

The main points discussed at the Annual General Meeting held today are listed below.

<b>HIGHLIGHTS OF THE MEETING</b>
----------------------------------

1. All the items on the agenda were approved.
2. In addition to the agenda items, the Chairman highlighted the following points, which we summarise below:
  - a) On the subject of corporate governance, the Chairman referred to the proposals submitted for approval by the General Meeting concerning the renewal and composition of the Board of Directors. These proposals form part of the evolution of the Group's governance model and are aimed at maintaining a balanced structure in terms of independence (50%), diversity (40%) and adequate shareholder representation, in line with good governance recommendations.
  - b) In the area of sustainability, he highlighted the progress made in integrating environmental, social and governance criteria into the Group's strategy and operations, as well as the approval of a new Strategic Sustainability Plan aligned with the overall Strategic Plan, with the aim of reinforcing the Group's commitment to responsible, long-term growth.
  - c) Share performance during the 2025 financial year was very positive, with growth of 48%, reflecting the market's confidence in the Group's strategy and execution, as well as its shareholder remuneration policy. This reaffirms the Company's commitment to sustainable remuneration.
  - d) Shareholder returns: a cash dividend of 0.041 euros, paid in January 2026, and 0.087 euros, payable on **6 July**:

- Last day on which shares are traded with dividend rights (Last Trading Date): 1 July.
- Date from which shares will be traded without entitlement to the dividend (Ex-Date): 2 July.
- Record date for shareholders entitled to receive the dividend: 3 July.

The total dividend therefore amounts to 0.128 euros per share, representing a payout of 50% of the consolidated net profit for 2025.

3. For his part, the CEO highlighted the following points during his speech:

- a) During the 2025 financial year, the Group made progress in implementing the 2025–2030 Strategic Plan presented in April of that year, focusing on sustainable growth, internationalisation, leadership through science, operational and commercial excellence, and the development of industrial and organisational capabilities. The Company has continued to strengthen its position as a pharmaceutical group with an international presence and an operational structure tailored to its growth objectives.
- b) In the 2025 financial year, two significant acquisitions were completed: SIFI and EDOL. These transactions have enabled the Group to strengthen its international presence and its position in the field of ophthalmology. Over recent months, progress has been made in the integration processes, both in the commercial and industrial spheres and within the organisation, with the aim of realising synergies and optimising the Group's structure.
- c) In the field of R&D, the Group has strengthened its governance by promoting greater discipline in prioritisation, decision-making and execution. The strategy combines scientific rigour and ambition, based on the selective development of new molecules, their integration into the portfolio and co-development, and is structured around four pillars: a balanced portfolio, life-cycle management, external collaboration and proprietary technology platforms.

Ophthalmology is establishing itself as a strategic area and a driver of growth following the acquisitions of SIFI and EDOL, with more than seven launches forecast between 2026 and 2027 and international expansion of the portfolio. Furthermore, the Group continues to maximise the value of key products such as bilastine and mesalazine.

In the field of rare diseases, Akantior stands out as the first treatment approved in Europe for Acanthamoeba keratitis; it is already reimbursed in Spain and Italy and is expanding, with progress in the US and potential for new indications.

- d) During the financial year, the Company has continued to develop initiatives aimed at improving commercial and operational efficiency, including the introduction of new data analysis tools and the evolution of customer relationship models. Furthermore, projects for the continuous improvement of processes in the industrial and operations sectors have been advanced.
- e) The new plant in Derio is a key element of the Group's industrial strategy, as it enables an increase in production capacity and an improvement in operational efficiency. During the 2025 financial year, costs associated with the implementation and transition process were incurred, the positive impact of which is expected in the coming financial years.
- f) The Group has continued to pursue initiatives aimed at strengthening its corporate culture, developing talent and adapting the organisation to new strategic objectives.
- g) The 2025 financial year saw revenue exceed **627 million euros**, driven both by business performance and by the incorporation of acquired companies, with organic growth also proving positive. In terms of operating performance, EBITDA stood at around 118 million euros, having been affected by costs associated with the integration of acquisitions and by costs linked to the relocation of production to the new plant in Derio. However, excluding these effects, the underlying business has performed in line with the forecasts communicated to the market. The Company anticipates a gradual improvement in profitability over the coming financial years as these costs normalise, the integration of the acquired companies is completed and the expected synergies are realised, whilst maintaining a solid financial structure and debt levels in line with the Group's forecasts that the net debt/EBITDA ratio will not exceed 2x EBITDA.

25 June 2026